^
    CANCER:

    Acute Lymphocytic Leukemia





    Show legend
    Group by Gene:
    Include preclinical:

    CD19-targeted CAR-T immunotherapy
    brexucabtagene autoleucel
    tisagenlecleucel-T
    		0
    CD19-targeted CAR-T immunotherapy
    PBCAR0191
    CTX110
    AUTO1
    pCAR-19B
    ISIKOK-19
    nelarabine
    		1
    DNA synthesis inhibitor
    clofarabine
    thioguanine
    nedaplatin
    2
    Bcr-abl tyrosine kinase inhibitor
    nilotinib
    olverembatinib
    3
    Proteasome inhibitor
    bortezomib
    carfilzomib
    4
    Tubulin polymerization inhibitor
    vincristine liposomal
    vincristine
    5
    Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    cytarabine + etoposide IV + mitoxantrone
    6
    CD38 inhibitor
    daratumumab
    isatuximab-irfc
    7
    Protein synthesis inhibitor, Asparagine depleter
    recombinant Erwinia asparaginase
    ponatinib
    		8
    Multi-tyrosine kinase inhibitor
    nintedanib
    vandetanib
    cabozantinib capsule
    9
    Bcl2 inhibitor
    venetoclax
    10
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    11
    Topoisomerase II inhibitor
    etoposide IV
    doxorubicin hydrochloride
    12
    Asparagine depleter
    eryaspase
    13
    CD20 inhibitor
    rituximab
    ofatumumab
    Menin-MLL inhibitor
    		14
    Menin-MLL inhibitor
    SNDX-5613
    DS-1594
    15
    PI3Kδ inhibitor
    idelalisib
    16
    IDH2 inhibitor
    enasidenib
    17
    CD19 inhibitor
    YT-19
    18
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
    bosutinib
    19
    Proteasome inhibitor, CD20 inhibitor
    rituximab + bortezomib
    20
    VEGFR inhibitor
    axitinib
    21
    ALK inhibitor
    crizotinib
    22
    DNA methylation inhibitor
    azacitidine
    23
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    CALGB 10403
    COG AALL0232
    MRC UKALLXII / ECOG2993
    Linker 4-drug
    CALGB 8811 Larson
    USC / MSKCC ALL
    		24
    Chemotherapy
    PETHEMA ALL-96
    GRAALL-2005
    DFCI ALL
    COG AALL0434
    FLAG-IDA
    VPD
    ADE
    25
    CAR-T immunotherapy
    CAR-T immunotherapy
    26
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    27
    Tyrosine kinase inhibitor, Chemotherapy
    CVAD + Tyrosine kinase inhibitor
    28
    CD22-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
    CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy
    29
    CD7-targeted CAR-T immunotherapy
    CD7-targeted CAR-T immunotherapy
    30
    Sphingosine kinase inhibitor
    Sphingosine kinase inhibitor
    31
    JAK inhibitor
    JAK inhibitor
    32
    CD70-targeted CAR-T immunotherapy
    CD70-targeted CAR-T immunotherapy
    33
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    34
    JAK1 inhibitor, JAK2 inhibitor, T-lymphocyte cell therapy
    T-lymphocyte cell therapy + ruxolitinib
    35
    CD19 inhibitor, CD3 agonist
    blinatumomab
    36
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    37
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, CAR-T immunotherapy, PDGFR β antagonist, EphA2 receptor antagonist
    CAR-T immunotherapy + dasatinib
    38
    CD22-targeted antibody-drug conjugate, DNA replication inhibitor
    inotuzumab ozogamicin
    39
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    40
    CD19 inhibitor, CD3 agonist, CD22-targeted antibody-drug conjugate, DNA replication inhibitor
    blinatumomab + inotuzumab ozogamicin
    41
    THF dehydrogenase inhibitor, Alkylating agent, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
    cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
    42
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
    cytarabine + methotrexate
    43
    PRPP amidotransferase inhibitor, DNA synthesis inhibitor
    mercaptopurine
    44
    Aspartate-ammonia ligase inhibitor, Asparagine depleter
    pegaspargase
    calaspargase pegol-mknl
    45
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, DNA intercalator
    vincristine + daunorubicin + pegaspargase + nelarabine
    46
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA inhibitor
    ifosfamide + etoposide oral + mitoxantrone
    47
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
    vincristine + mitoxantrone + pegaspargase
    48
    PD-L1 inhibitor, Bcr-abl tyrosine kinase inhibitor
    PD-L1 inhibitor + nilotinib
    49
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter, DNA intercalator
    vincristine + daunorubicin + pegaspargase
    50
    CD19 inhibitor, CD3 agonist, CD20 inhibitor
    rituximab + blinatumomab
    51
    Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor, DNA synthesis inhibitor
    cyclophosphamide + etoposide oral + clofarabine
    cyclophosphamide + etoposide oral + nelarabine
    52
    THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
    cytarabine + methotrexate + idarubicin hydrochloride
    53
    Tubulin polymerization inhibitor, Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor + vincristine
    54
    CD19 inhibitor, Bcr-abl tyrosine kinase inhibitor, CD3 agonist, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + blinatumomab
    55
    CD19 inhibitor, CD3 agonist, Multi-tyrosine kinase inhibitor
    ponatinib + blinatumomab
    56
    STAT5 inhibitor, JAK2 inhibitor, FLT3 inhibitor
    CEP-701
    57
    Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
    venetoclax + ponatinib
    58
    CD38 inhibitor, Bcl2 inhibitor
    venetoclax + daratumumab
    59
    CD19 inhibitor, CD3 agonist, PD1 inhibitor
    nivolumab + blinatumomab
    60
    Bcr-abl tyrosine kinase inhibitor, CD22-targeted antibody-drug conjugate, DNA replication inhibitor, Src kinase inhibitor
    bosutinib + inotuzumab ozogamicin
    61
    Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    flumatinib
    62
    Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor
    venetoclax + flumatinib
    63
    Topoisomerase II inhibitor, HDAC inhibitor, Proteasome inhibitor
    bortezomib + vorinostat + mitoxantrone
    64
    Bcr-abl tyrosine kinase inhibitor, Bcl2 inhibitor
    venetoclax + olverembatinib
    65
    PI3K inhibitor, mTOR inhibitor
    RTB101
    66
    CD19 inhibitor, CD3 agonist, PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab + blinatumomab
    67
    CD19 inhibitor, Bcr-abl tyrosine kinase inhibitor, CD3 agonist
    blinatumomab + olverembatinib
    68
    GART inhibitor
    T-64
    69
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    70
    TTK inhibitor
    S81694
    71
    TTK inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + nilotinib + S81694
    72
    XPO1 inhibitor, Nuclear export inhibitor
    KPT-8602
    73
    HDAC inhibitor
    panobinostat
    romidepsin
    74
    Glutaminase inhibitor
    CB-839
    75
    Electron transport complex I inhibitor
    IACS-010759
    76
    JAK inhibitor, SYK inhibitor
    ALXN2075
    77
    PLK1 inhibitor, Bcl2 inhibitor
    venetoclax + NBL-001
    78
    CD19 inhibitor, CD16A inhibitor, IL-15R stimulant
    FT596
    79
    P21-activated kinase inhibitor
    FRAX597 + PF-3758309
    80
    Alkylating agent
    cyclophosphamide
    ACHM-025
    81
    CD9 inhibitor
    KBA1412
    82
    Tubulin polymerization promoter
    carboplatin
    83
    AKT inhibitor
    MK-2206
    84
    mTOR inhibitor
    sirolimus
    85
    BET inhibitor
    JQ-1
    86
    MCL1 inhibitor, Bcl2 inhibitor
    S63845 + S55746
    87
    JAK2 inhibitor
    CHZ868
    88
    AKT inhibitor, p70S6K inhibitor
    CCT128930
    89
    Aurora kinase A inhibitor
    MLN8237
    90
    Ubiquitin pathway modulator, GSPT1 degrader
    CC-90009
    91
    Bcl2 antagonist
    ABT-737
    92
    RAS inhibitor, Vav3 inhibitor
    IODVA1
    93
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist, JNK inhibitor
    dasatinib + JNK-IN-8
    94
    SYK inhibitor
    GS-9973
    95
    STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor
    asciminib
    96
    DNA replication inhibitor, CD19-targeted antibody-drug conjugate
    SGN-CD19B
    97
    MEK inhibitor, SYK inhibitor
    selumetinib + GS-9973
    98
    HSP90 inhibitor
    aminoxyrone
    99
    ROR1-targeted antibody-drug conjugate, Microtubule inhibitor
    MK-2140
    100
    SYK inhibitor, FLT3 inhibitor
    CB-659
    101
    CD123-targeted antibody-drug conjugate, DNA replication inhibitor
    IMGN632
    102
    Topoisomerase II inhibitor, ROR1-targeted antibody-drug conjugate
    VLS-211
    103
    XPO1 inhibitor, Bcl2 inhibitor
    venetoclax + selinexor
    104
    XPO1 inhibitor
    selinexor
    105
    DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    cytarabine
    106
    DHODH inhibitor, ATR inhibitor
    M6620 + BAY2402234
    107
    p53 reactivator
    APR-246
    108
    JAK3 inhibitor, JAK1 inhibitor, JAK2 inhibitor
    tofacitinib
    109
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    venetoclax + dasatinib
    110
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    111
    JAK1 inhibitor, JAK2 inhibitor, Bcl2 inhibitor
    venetoclax + ruxolitinib
    112
    SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
    MEDI7247
    113
    THF dehydrogenase inhibitor
    pralatrexate
    114
    IL-7R antagonist
    OSE-127
    115
    Microtubule inhibitor, CD74-targeted antibody-drug conjugate
    STRO-001
    116
    eIF4G1 inhibitor, Bcr-abl tyrosine kinase inhibitor, NF-κB inhibitor, mTORC1 inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist, AKT inhibitor
    dasatinib + SBI-756
    117
    HSP90 inhibitor, HDAC inhibitor
    vorinostat + BMS-722782
    118
    JAK inhibitor, HDAC inhibitor, SYK inhibitor
    vorinostat + ALXN2075
    119
    5T4-targeted antibody-drug conjugate, Microtubule inhibitor
    PF-06263507
    120
    Menin-MLL inhibitor, MEK inhibitor
    selumetinib + SNDX-5613
    121
    MDM2 protein degrader
    MX69-114b
    122
    Survivin inhibitor
    PC-002
    123
    CDK9 inhibitor
    PRT2527
    124
    CCR4 receptor antagonist
    mogamulizumab-kpkc
    125
    HER2 inhibitor
    trastuzumab
    126
    Topoisomerase I inhibitor
    irinotecan
    127
    CSF-1R inhibitor, FMS kinase inhibitor
    OPN-7486
    128
    PARP inhibitor
    olaparib
    129
    mTOR inhibitor, γ-secretase inhibitor
    sirolimus + MRK003
    130
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    131
    mTORC1 inhibitor
    nanoparticle albumin-bound rapamycin
    132
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    133
    Multi-tyrosine kinase inhibitor, FLT3 inhibitor
    FLT3 inhibitor + gilteritinib
    No biomarker
    BCR-ABL1 fusion
    BCR-ABL1 T315I
    BCR-ABL1 mutation
    BCR-ABL1 Q252H + BCR-ABL1 V299L
    BCR-ABL1 E255K
    BCR-ABL1 N49S
    BCR-ABL1 M244V
    BCR-ABL1 V379I
    BCR-ABL1 T315L
    BCR-ABL1 D276G
    BCR-ABL1 V289A
    BCR-ABL1 F359V
    BCR-ABL1 F317I
    BCR-ABL1 V299L
    BCR-ABL1 T315I + ABL1 E255V
    BCR-ABL1 T315I + ABL1 E255K
    BCR-ABL1 F317I + ABL1 F317C
    BCR-ABL1 F317I + ABL1 F317C + ABL1 F1317L
    BCR-ABL1 T315M
    BCR-ABL1 V229L
    BCR-ABL1 Y253H
    BCR-ABL1 E255V
    BCR-ABL1 F317L
    BCR-ABL1 F359I
    BCR-ABL1 F359C
    BCR-ABL1 F317C
    BCR-ABL1 F317V
    BCR-ABL1 T315A
    BCR-ABL1 G250E
    CD20 positive
    CD20 expression
    JAK2 fusion
    JAK2 F694L
    STRBP-JAK2 fusion
    JAK2 R938Q
    JAK2 R683G
    ABL1 fusion
    SH2B3 alteration
    ABL1 T315I
    SH2B3 deletion
    ABL1 E255K
    ABL1 G250E + ABL1 D276G + ABL1 T315I
    ABL1 exon 4 deletion + ABL1 T315I
    EPOR rearrangement
    CRLF2 rearrangement + JAK2 fusion
    IL7R mutation
    ABL2 fusion
    IL7R expression
    CD19 positive
    CD19 deletion
    KMT2A rearrangement
    MLL-AFF1 fusion
    CD22 positive
    CD22 overexpression
    CD22 expression
    CRLF2 rearrangement
    FOXP1-ABL1 Fusion
    TP53 mutation
    CRLF2 overexpression
    ATF7IP-PDGFRB fusion
    TCF3-PBX1 fusion
    ATF7IP-PDGFRB translocation
    PAX5 mutation
    TP53 deletion
    PAX5 fusion
    TCF3-PBX1 rearrangement
    Chr t(3;9)(p13;q34) FOXP1/ABL1
    CRLF2 mutation
    IKZF1 deletion + PAX5 deletion
    KMT2A rearrangement + CD19 positive
    IKZF1 mutation
    PD-1 overexpression
    NUP214-ABL1 fusion
    CD58 expression
    NCOR1-LYN fusion
    IKZF3 mutation
    CSF3R M696T
    MLL-MLLT1 fusion
    EBF1-PDGFRB fusion
    GOLGA5-JAK2 fusion
    TP53 mutation + IKZF1 mutation
    TP53 mutation + IKZF3 mutation
    PDGFRB fusion
    INPP5D-ABL1 fusion
    SET-NUP214 fusion
    Chr t(3;11) + KMT2A-LARS2 fusion
    TET2 mutation + NRAS mutation
    CD19 negative + CD20 negative + CD22 negative
    CDKN2A deletion
    PAK4 deletion
    ETV6-NTRK3 fusion
    IL17A rs3819024
    IDH2 mutation
    CSF1R fusion
    CD19 positive + CD20 positive
    ABCB1 3435C>T
    IKZF1 deletion + CDKN2B deletion
    IKZF1 deletion + CDKN2A deletion
    PDGFRB C843G
    IKZF1 deletion
    NUP214-ABL1 rearrangement
    Chr t(4;11)(q21;q23)
    MLL translocation
    TPBG expression
    MCL1 underexpression
    MYC underexpression
    JAK1 S646F
    IL3RA expression
    SLFN11 expression
    NRAS mutation
    KRAS mutation
    P2RY8-CRLF2 fusion
    NRAS G12D
    PRPS1 A190T
    PRPS1 S103T
    CCND3 deletion
    JAK3 M511I
    SLC1A5 underexpression
    BCR-JAK2 fusion
    MLL rearrangement
    NOTCH1 mutation
    MYB-TYK2 fusion
    BCL2L1 underexpression
    AGGF1-PDGFRB fusion
    PRC2 mutation
    PCDHB15 overexpression
    TCRB-LCK translocation
    GSPT1 deletion
    AKT2 expression
    TCF3-EPAS1 fusion
    MEF2C overexpression
    IL22 overexpression
    RPL10 R98S
    NT5C2 mutation
    NT5C2 R367Q
    FGFR1 rearrangement + Chr t(8;13)
    MLL-AFF1 fusion + KRAS mutation
    MLL-AFF1 fusion + NRAS mutation
    MLL-MLLT3 fusion
    RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
    ROR1 expression
    MLL rearrangement
    HER-2 expression
    SF3B1 K666N
    JAK3 mutation
    SNX2-ABL1 fusion
    CD38 expression
    STAT5B-BAG1 fusion
    GOLGA4-JAK2 fusion
    DNMT3B overexpression
    PAX5-JAK2 fusion
    AKR1C3 overexpression
    HGF-L
    BCL2L1 overexpression
    CD74 expression
    TNFRSF13C expression
    BCL2L2 overexpression
    ZEB2-JAK2 fusion
    ATF7IP-JAK2 fusion
    DNMT3A mutation
    CD9 expression
    FOXO1 underexpression
    PAK2 overexpression
    CD22 underexpression + BCL2 overexpression
    ETV6-ABL1 fusion
    SSBP2-CSF1R fusion
    RCSD1-ABL2 fusion
    IGH-CRLF2 fusion + JAK2 R867Q
    JAK1 S646F
    IGH-CRLF2 fusion + JAK2 R683G
    IGH-CRLF2 fusion
    IGH-CRLF2 fusion + JAK2 GPInsR683
    P2RY8-CRLF2 fusion + JAK2 QGinsR683
    NOTCH1 expression
    MDM2 overexpression
    CD70 expression
    KMT2A rearrangement + RAS mutation